Key market opportunities in the RNA Therapy Clinical Trials sector include an increase in chronic and rare diseases, advancements in delivery technologies like lipid nanoparticles, robust venture ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

New York, May 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global RNA Interference Technology Market - Premium Insight, Competitive News Feed Analysis, Company ...

Lethal and rescuer genes are defined as genes that when inactivated result in cell death or enhanced cell growth, respectively. The ability to identify these genes in large-scale automated screening ...

The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

Through its innovative asymmetric siRNA platforms, OliX Pharmaceuticals is opening up huge opportunities in RNA interference-therapeutic development to address unmet needs for various indications ...

KANSAS CITY, Mo.--(BUSINESS WIRE)--TechAccel today announced the launch of RNAissance Ag LLC, a new company that holds the exclusive license to RNA-interference technology in partnership with the ...

For decades, the central dogma of molecular biology—DNA makes RNA, RNA makes protein, protein makes phenotype—was the guiding framework for understanding inheritance and disease. This model explained ...

Please provide your email address to receive an email when new articles are posted on . ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Bart Leroy, MD, PhD, speaks about RNA ...

Business Strategy and Outlook Ionis is a leader in RNA-based therapies, and its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster ...

LONDON, Feb 26 (Reuters) - Britain's Ark Therapeutics said on Thursday it had filed a patent application for a new genetic technique that represents an advance in so-called RNA interference technology ...